宜明昂科-B(01541)今日盘中股价大幅上涨5.15%，引起了市场的广泛关注。
消息面上，公司发布公告称，其独立研发的IMM0306联合来那度胺治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验，已顺利完成首例患者给药。IMM0306是一种靶向CD47及CD20的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子，该进展被视为公司核心研发管线的重要里程碑。
根据公告，IMM0306通过独特的机制阻断“别吃我”信号，激活免疫细胞以消除恶性B细胞，同时旨在降低毒性，改善治疗效果。公司拥有该产品的全球知识产权及商业化权利，此临床进展增强了市场对其创新疗法未来商业化潜力的信心，从而推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.